Atlantic Equities analyst John Heagerty upgrades First Republic Bank (NYSE:FRC) from Neutral to Overweight and lowers the price target from $210 to $188.
BetterLife’s Non-Hallucinogenic LSD’s Clinical Studies, Braxia’s Psychedelic Treatments Continue
Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting Major Depressive Disorder (MDD.)
